

Covid Vaccine Manufacturing, Distribution, Global Supply Chain

 [pfizer.com/science/coronavirus/vaccine/manufacturing-and-distribution](https://www.pfizer.com/science/coronavirus/vaccine/manufacturing-and-distribution)

Manufacturing and Distributing the COVID-19 Vaccine

Pfizer consistently and diligently monitors the supply of our medicines. We operate one of the most sophisticated supply chain systems in the industry, with over 35 Pfizer-owned sites and over 300 suppliers globally, which provides capacity and redundancy as needed. Our manufacturing and supply chain professionals have been working non-stop to ensure that the global supply of Pfizer medicines continue to be available to patients. We have implemented an unprecedented and comprehensive preparedness plan to control our site operations and will continue to provide timely updates if there is any new information to be shared.

A Cold Chain Overview

with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group

Cold Chain Distribution

How is the cold chain distribution for the Pfizer and BioNTech investigational vaccine being managed?

A Look at Cold Storage & Distribution

with Mike McDermott, President, Pfizer Global Supply

A Look at Cold Storage & Distribution

with Mike McDermott, President, Pfizer Global Supply

- Where is the Pfizer-BioNTech COVID-19 vaccine made?
- How is the Pfizer-BioNTech COVID-19 vaccine being distributed?
- What is the path of a vaccine from Pfizer's facilities to where it's distributed to patients?

- How will Pfizer maintain vaccine integrity during distribution?

Pfizer is a proven, reliable multinational vaccine producer, supplying vaccines to more than 165 countries. Today, Pfizer manufactures more than 200 million doses of Pfizer vaccines annually and is one of the largest sterile injectables suppliers in the world, producing more than 1 billion sterile units per year. We have experience working with customers in all markets to ensure success.

We have years of proven experience in supply chain and cold chain management, and we are accelerating the development of innovative technologies to further advance our capabilities as a supply chain leader.

Our track record gives us confidence in our ability to quickly scale and manufacture and distribute large quantities of a high-quality COVID-19 vaccine, leveraging multiple sites in the US and Europe.

We have also developed packaging and storage innovations to be fit for purpose to meet the needs of our global network.

We have developed detailed logistical plans and tools to support effective vaccine transport, storage and continuous temperature monitoring. Our distribution is built on a flexible just-in-time system which will ship the frozen vials to the point of vaccination.

The intent is to utilize Pfizer-strategic transportation partners to ship by air to major hubs within a country/region and by ground transport to dosing locations.

- What is a “cold chain”?
- How is Pfizer utilizing a cold chain process to distribute its vaccine?
- How can you prevent a cold chain failure?
- How do hospitals and pharmacies keep vaccines cold?

COVID-19 Vaccine U.S. Distribution Fact Sheet

More information about our work to manufacture and distribute the Pfizer-BioNTech COVID-19 vaccine.

How Pfizer Scaled Up Manufacturing of Their COVID-19 Vaccine

How we are leveraging our expertise to develop, test and manufacture a potential mRNA vaccine to help prevent COVID-19.

For additional information about Pfizer, please see our filings with the U.S. Securities and Exchange Commission, including the information provided in the sections captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”.

Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

© 2024 Pfizer Inc. All rights reserved